Equity
€1.1m ▲ 63.4%
SYNAPSIS has made a profit without a break since 2009.
SYNAPSIS
Lifetime
18 annual accounts with figures on one time axispeak €734,298 (2025)
€734,298▲ 214%
lowest -€39,215 (2008)
€426,593▲ 263%
peak €1.1m (2025)
€1.1m▲ 63.4%
€796,306▲ 3.2%
Board1 name since 2008
1 directorCaroline DEPUYDT
Owners
Documentsfilings and deeds
28-07-20263 days before the deadline
2025micro format
Gross margin from €233,832 to €734,298Result from €117,668 to €426,593Company renamed from DEPUYDT CAROLINE to SYNAPSIS 17-11Equity from €687,936 to €1.1mCash from €19,774 to €218,428
Key points
from the 2025 annual accountsResult
€426,593 ▲ 263%
The result rose in 2025 from €117,668 to €426,593.
Investments
€9,056 0.1 × depreciation
Green is investment, beige is depreciation.
Liquidity
3.19 was 1.95 in 2024
Short-term debts rose from €283,380 to €355,875.
Filings
18 annual accounts since 2008
Nine of the last ten came late. The 2024 accounts came latest: 273 days after the end of the period.
Position in the sector
€426,593
Higher net result than 95% of companies in human health. Sector median €60,070 · 20,754 companies.
Checked score
94
Excellent
Financially stronger than 56% of micro companies in human health (NACE 86)
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
< 0.1% Very low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: < 0.1% across 24,192 companies (NACE 86, micro).
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: < 0.1%lowest value
01-2025: < 0.1%● unchanged vs 12-2024lowest value
02-2025: < 0.1%● unchanged vs 01-2025
03-2025: < 0.1%● unchanged vs 02-2025
04-2025: < 0.1%● unchanged vs 03-2025
05-2025: < 0.1%● unchanged vs 04-2025
06-2025: < 0.1%● unchanged vs 05-2025
07-2025: < 0.1%● unchanged vs 06-2025
08-2025: < 0.1%● unchanged vs 07-2025
09-2025: 0.5%▲ +0.5 percentage points vs 08-2025
10-2025: 0.5%● unchanged vs 09-2025
11-2025: 0.5%● unchanged vs 10-2025
12-2025: 0.5%● unchanged vs 11-2025
01-2026: 0.5%● unchanged vs 12-2025
02-2026: 0.5%● unchanged vs 01-2026
03-2026: 0.6%▲ +0.1 percentage points vs 02-2026
04-2026: 0.6%● unchanged vs 03-2026
05-2026: 0.6%● unchanged vs 04-2026
06-2026: 0.5%▼ -0.1 percentage points vs 05-2026
07-2026: 0.6%▲ +0.1 percentage points vs 06-2026highest value
08-2026: < 0.1%▼ -0.6 percentage points vs 07-2026
09-2026: < 0.1%● unchanged vs 08-2026
10-2026: < 0.1%● unchanged vs 09-2026
11-2026: < 0.1%● unchanged vs 10-2026
Financial strengthStrong
Score breakdown
raises risk
1 of the last 3 accounts late
lowers risk
Sector: Human health activities (NACE 86)
Size: total assets €1.9m
Figures for financial year 2025 (filed on 28-07-2026)
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 86, micro). It does better than 47% of them on solvency, 36% on liquidity, 56% on profitability and 84% on growth.
The bankruptcy probability was computed on 10-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 17,811 companies had the same profile as SYNAPSIS has now. Each dot stands for 45 companies, two years later.
96.5%
were still trading
3.2%
stopped another way
0.3%
went bankrupt
That fits the bankruptcy probability of SYNAPSIS itself: < 0.1% within 12 months.
Test of the method
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 17,811 companies, not a prediction for SYNAPSIS. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €100,000 on 30-day terms is acceptable
Liquidity is ample, with a current ratio of 3.19 (1.95 in 2024), above the usual 1.5. Short-term debt is 18.5% and cash 11.4% of total assets. 41.5% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Five signals.
lowers riskraises riskneutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 28-07-2026, 3 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
3 days early
2024
273 days late
2023
30 days late
2022
25 days late
2021
8 days late
2020
31 days late
2019
31 days late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 56 days after the deadline. In the sector (NACE 86), the median for financial year 2024 was 7 days before the deadline, and 36% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 25 August (4 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
10-11-2026 today31-12-2026 year end31-07-2027 deadline
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0897006312
Company renamed from DEPUYDT CAROLINE to SYNAPSIS
Gazette deed
Change of role: DEPUYDT Caroline, from manager to director
“L’organisation,la promotion et/ou la gestion de formations diverses,mais également d’évènements,tels que…” (deed in French) · Gazette deed
General meeting of 22-11-2017
Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| SYNAPSIS Uccle | €1.9m | €734,298 | 58.5% | - |
| DRS. LAMONT-VERSCHUEREN Nazareth-De Pinte | €2.1m | €716,608 | 92.7% | - |
| DR. MICHAEL FRIED EN DR. JOANNA VERMEIJ Antwerp | €1.9m | €733,376 | 93.2% | - |
| Dokters Van fraeyenhove-Meireson Temse | €1.9m | €684,733 | 82.8% | - |
| Dr. Philip Vanparijs Sint-Niklaas | €2.1m | €717,203 | 93.0% | 1 |
| A-RHYTHMIC Hove | €2.2m | €740,137 | 88.6% | 1 |
| Dr. Jan Vanhove - MKA Kortenberg | €2.2m | €699,710 | 84.0% | - |
These companies have the same main activity as SYNAPSIS: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €1.9m and €2.2m, founded between 2006 and 2009.
Official details
Source: KBO- Status
- Active since 07-04-2008Normal situation
- Activity
- Specialist medical practiceNACE 86220
- Establishment unit
- 2.193.243.7391180 Uccle, since 02-04-2008
- Financial year end
- 31 December
- Peppol
- Reachable since 10-12-2025
Annual accounts 2025
- ≈ €1.1mestimated
- €1.9m▲ 31.6%
- Filing
- Filed on 28-07-2026, 3 days before the end of the filing period
Insights on SYNAPSIS
SYNAPSIS files the micro format. That format states no turnover. The gross margin rose from €5,808 in 2008 to €734,298 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about SYNAPSIS
- What is the company number of SYNAPSIS?
- The company number of SYNAPSIS is 0897.006.312. The VAT number is the same number with BE in front: BE 0897.006.312.
- Where is SYNAPSIS based?
- The registered office is at Jacques Pasturlaan 49, 1180 Uccle.Company details
- What does SYNAPSIS do?
- According to the KBO register, the main activity is specialist medical practice (NACE 86220).
- What is the legal form of SYNAPSIS?
- SYNAPSIS is a private limited company (BV).
- When was SYNAPSIS founded?
- SYNAPSIS was founded on 07-04-2008.
- Is SYNAPSIS still active?
- Yes, SYNAPSIS is an active enterprise in the KBO register.
- What is the turnover of SYNAPSIS?
- The turnover in financial year 2025 is ≈ €1.1m. This figure is estimated from the gross margin of €734,298 and 30 comparable companies (NACE 86220). It probably lies between €1.0m and €1.5m.Financials
- Is SYNAPSIS profitable?
- In financial year 2025, SYNAPSIS made a profit of €426,593.
- Where can I find the annual accounts of SYNAPSIS?
- SYNAPSIS filed 18 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of SYNAPSIS due?
- SYNAPSIS must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.